Oruka Therapeutics (NASDAQ:ORKA) Announces Quarterly Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) announced its quarterly earnings data on Monday. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03), FiscalAI reports.

Oruka Therapeutics Stock Down 1.4%

ORKA stock traded down $1.57 during mid-day trading on Wednesday, hitting $107.92. 393,705 shares of the company were exchanged, compared to its average volume of 1,082,335. The business has a fifty day simple moving average of $88.82 and a 200-day simple moving average of $71.29. Oruka Therapeutics has a 12-month low of $25.23 and a 12-month high of $115.51. The firm has a market capitalization of $7.15 billion, a P/E ratio of -51.04 and a beta of -0.34.

Analyst Ratings Changes

ORKA has been the topic of a number of recent research reports. Wedbush reiterated an “outperform” rating and issued a $165.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Mizuho set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 3rd. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.00.

Insider Transactions at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the transaction, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Klein sold 75,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at $84,996,011.40. This represents a 7.50% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 179,950 shares of company stock worth $16,492,680 over the last ninety days. Company insiders own 23.49% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.